Picture of Precipio logo

PRPO Precipio Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapValue Trap

Momentum

Relative Strength (%)
1m+3.37%
3m-15.87%
6m-20.55%
1yr-68.64%
Volume Change (%)
10d/3m+86.83%
Price vs... (%)
52w High-62.91%
50d MA+3.29%
200d MA-13.5%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-66.7%
Return on Equity-58.25%
Operating Margin-68.41%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Precipio EPS forecast chart

Profile Summary

Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Company’s technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its technology enables testing to be completed in one rapid scanning process. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.

Directors

Last Annual
December 31st, 2022
Last Interim
September 30th, 2023
Incorporated
March 6th, 1997
Public Since
July 18th, 2000
No. of Shareholders
38
No. of Employees
53
Sector
Healthcare Equipment & Supplies
Industry
Healthcare
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
1,420,125

PRPO Share Price Performance

Upcoming Events for PRPO

Q4 2023 Precipio Inc Earnings Release

Q1 2024 Precipio Inc Earnings Release

Precipio Inc Annual Shareholders Meeting

Q2 2024 Precipio Inc Earnings Release

Similar to PRPO

Picture of Accelerate Diagnostics logo

Accelerate Diagnostics

us flag iconNASDAQ Capital Market

Picture of Acutus Medical logo

Acutus Medical

us flag iconNASDAQ Capital Market

Picture of Adapthealth logo

Adapthealth

us flag iconNASDAQ Capital Market

Picture of Aethlon Medical logo

Aethlon Medical

us flag iconNASDAQ Capital Market

Picture of Agape ATP logo

Agape ATP

us flag iconNASDAQ Capital Market

FAQ